Meeting reports
Respiratory syncytial virus (RSV) in man and animals Keywords: respiratory syncytial virus A comprehensive view was given of the clinical and economic problems associated with respiratory syncytial virus (RSV) diseases in man and animals, as well as their epidemiology and potential treatments.
RSV, a member of the Pneumovirus genus of the Paramyxoviridae family, is responsible for disease in man, cattle, goats and sheep. Other closely related viruses of this genus, the pneumonia virus of mice (PVM) and turkey rhinotracheitis virus (TRT), were also discussed.
To further understanding of the disease processes involved, it is important to be familiar with the virus structure. A single stranded RNA genome of approximately 15 000 nucleotides codes for 2 nonstructural and 10 struural proteins. Ofthe stuctural proteins, two are glycosylated, the F and G glycoproteins, which are responsible for fusion and attachment, respectively. Monoclonal antibodies against these glycoproteins allow further division of RSV into the antigenically distinct A and B subtypes.
Dr E Stott (Institute for Research on Animal Diseases, Compton) opened the talks by describing the disease in beef animals. The situation in calves is really very similar to that seen in infants, with a clinical infection culminating in acute bronchiolitis. As with man, the morbidity is highest in early life, in calves of 2-4 months of age, when infection occurs in the face of high levels of maternally derived antibodies. Shedding of large amounts of virus for several days occurs at the time of primary infection, but in subsequent reinfections, which is a common feature, disease severity and virus excretion are far less marked. What is of great interest and contrasts with the human situation is the efficacy of immunization. In cattle, immunization was initially tried using a formalin inactivated vaccine, which produced a good antibody response, that was not protective. Protective antibody was induced in calves using a live attenuated vaccine administered intramuscularly. Seroconversion was not adversely affected by maternally derived antibody, and efficacy data shows a clear reduction in disease morbidity and mortality following primary infection.
Dr Stott also looked at future prospects for prevention, using recombinant antigens as immunogens, possibly utilizing vaccinia as a vector, and at the availability of monoclonal antibodies to the F glycoprotein which might represent the first specific treatment.
The second speaker, Professor C Pringle (Warwick University) described the taxonomy and structure of the viruses, and the clinical diseases, using RSV and PVM as specific examples. PVM was the first paramyxovirus to be isolated. It causes a persistent infection in rodents, e.g. Syrian hamsters, cotton rats and rabbits. Recent seroepidemiological studies of respiratory tract disease in man now support the theory that PVM or an antigenically similar virus may be responsible for clinical disease. This is of importance, as no cross neutralization occurs between RSV and PVM, although a relationship between some of their proteins can be shown by monoclonal and immunoprecipitation techniques, which may have considerable importance in terms of possible future vaccine development.
Dr D Alexander.(Central Veterinary Laboratory, Weybridge) unveiled the recent emergence ofa newly identified Pneumovirus, TRT. An epidemic of respiratory disease in turkeys caused by this virus appeared in South Africa in 1972. It was not until June 1985 that it first became evident in the UK. A clinical syndrome of respiratory disease with ocular and nasal discharge, conjunctivitis and sinusitis, together with submandibular, periorbital and infraorbital swelling was distinctive ofthe infection, which was sometimes associated with neurological signs and inner ear infection. Virtually all birds in a flock were affected, and if secondary infection supervened then a mortality rate of up to 90% could be expected. Within 10-15 weeks ofthe localized appearance ofthis disease in East Anglia, it had spread to much of England and Wales. Investigations resulted in the isolation of TRT, and seroepidemiology confirmed the spread of this new virus. It is now subsequently recognized that there is a similar clinical entity-Swollen Head Disease of Chickensalso due to TRT infection, which has a very high morbidity and markedly impairs egg production.
Dr G Tomms (Newcastle), the fourth speaker, considered RSV diseases of man. He started with a historical perspective, describing studies which validated the major role of RSV as a respiratory pathogen, and showing that the incidence of clinical disease remains similar to that initially investigated in Newcastle in the late 1940s. RSV shows a marked seasonal pattern, producing predictable annual epidemics in the UK between January and March. During the incubation period of 3-6 days the virus replicates in the upper respiratory tract and is shed from there, with the clinical picture of fever, cough and coryza. Spread from the upper to the lower respiratory tract may occur, with consequent bronchiolitis and pneumonia. Everybody succumbs to RSV infection, most commonly in the first years and often in the early months of life, despite the theoretical protection of maternally derived antibodies. In fact, it is the presence of these specific antibodies which may contribute to the pathogenesis of disease, in terms of complex reactions between virus and maternal IgG in the lungs. This theory is strengthened by experience of an inactivated vaccine developed 25 years ago, which produced a good humoral response, but when the vaccinees were exposed to RSV during subsequent epidemic periods they developed a far more serious clinical disease than unvaccinated children.
Dr Toms also briefly reviewed the detailed immunological response to infection. In some individuals a good IgE response occurs, which has now been shown to correlate with an increased level of histamine in the bronchial secretions, and consequently marked wheezing. Interferon plays virtually no part in protection or reduction of virus shedding. It appears that the high level ofIgA found in colostrum can give some protection. Cell mediated immunity may feature strongly in the pathogenesis, severe clinical disease possibly being associated with defective cytotoxic T-cell function. Although RSV infection is very significant in childhood, and is also recognized as a major cause of otitis media, and is one of the incriminated infectious agents behind the Sudden Infant Death Syndrome (SIDS), it is important not to forget infection in the elderly, which is often fatal in combination with a secondary bacterial pneumonia.
The final speaker Dr J Snel (ICN Pharmaceuticals) detailed their evidence about the efficacy ofRibavirin in the treatment of RSV infections which led to its licensure in the UK last year. Ribavirin, a synthetic nucleoside analogue resembling guanosine and inosine, was manufactured in 1970. It has a broad spectrum of activity, particularly against RNA viruses, as it appears to interfere with the expression of messenger RNA and viral protein synthesis. It has been shown that for infants severely ill with RSV lower respiratory tract disease, often associated with underlying immunological or cardiopulmonary conditions, then Ribavirin treatment may be beneficial. In such circumstances the drug is best delivered by a small particle aerosol generator (SPAG) into an oxygen hood or tent, or into an endotracheal tube. Treatment regimens involve delivery for up to 20 hours a day for an average of 3-5 days, resulting in a rapid reduction in symptoms and viral excretion when compared to placebo treatment groups. The drug appears to be very safe, but when given orally or intravenously, accumulation in red cells is associated with a dose dependent haemolytic anaemia. This side effect has not been reported as a problem when the delivery route is via a SPAG.
In conclusion the meeting addressed all aspects of RSV and related viruses of man and animals. I found the aspects of disease outside the human host quite fascinating and in consequence the meeting very educational. Without doubt much useful information can be gained from exchanging experiences of animal and human infections, and future meetings along these lines would be welcomed. I am grateful for the SKF Research Fellowship which enabled me to attend the meeting. Mr Lawson opened with two main themes: we have little to learn from others in the area of clinical care; we have much to learn in matters oforganization and humanization. He was confident in his assertion of our clinical superiority. Developing countries are now in a position similar to the one we were in 100 years ago with mothers and children suffering from preventable illnesses and from the pathology of neglect. The fall in maternal mortality in the UK in the last 50 years has been due to a combination of factors: the use of chemotherapy in the 1930s, the advent of the NHS in 1948 and the increase in hospital rather than home deliveries. Now only 1% of babies are born at home, the exact opposite of the figure in developing countries. He was not, however, complacent about our present performance; our deaths could be reduced by 50% if full use were made of resources available.
Paul Grint Lecturer in Clinical Virology
A major change in parents' preoccupations in Britain has been their focus on children's quality of life rather than on mere survival. Nowadays everyone expects offspring who will pass at least two A levels, preferably with one S as well.
Moving to ways in which we can learn he listed five. First, we can learn much from developing countries about the ways to prevent mothers from feeling isolated. Even in Newcastle, the home of brown ale and the macho man, 85% of fathers now attend their child's birth but far more should be done to prepare them and their family to welcome the new baby and to support the mother once she is home.
A second point was that much money is wasted on antenatal wards in Britain. They tend to be full of women who are not sick and do not need highly qualified staff looking after them. He cited the maternity villages that exist in Africa, adjacent to hospitals but organized by a warden rather than medical staff.
The use of resources was also a theme for his third point: when money is in short supply it is important to use a risk approach to identify those who need the most expensive care. We all know ofthe poor outlook for the mother who is very old or very young, very small or sickly, but somehow such women can easily get lost in the British Health Service conveyor belt.
The training of doctors in obstetrics was his fourth point. Most antenatal and almost all postnatal care can be offered by GPs who will in any case be looking after the child later. Why should we have training in obstetrics or paediatrics and not, as in developing countries, have people who specialize in both, trained in maternal and child health? 0141-0768/89/ 010057-02402.00/0 ©1989 The Royal Society of Medicine
